Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Prevacid
Lansoprazole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lansoprazole DR Capsules 30 mg | EXPERIMENTAL | Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited |
| Prevacid 30 mg Capsules | ACTIVE_COMPARATOR | Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA |
| Name | Type | Description |
|---|---|---|
| Lansoprazole | DRUG | Lansoprazole DR Capsules 30 mg |
Inclusion Criteria: i. Provided written informed consent. ii. Subject who were healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg. iii. Subject having a body mass index between 18.0 and 29.9 (both inclusive), calculated as weight in Kg/height in m2...
Lansoprazole is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is a Phase 1 investigational agent studied in healthy adult volunteers. Its clinical development has focused on bioequivalence testing rather than a disclosed patient indication.
Lansoprazole targets ATP4A and ATP4B. It acts as an inhibitor of these targets. ATP4A and ATP4B form the gastric proton pump, the enzyme complex responsible for secreting acid into the stomach, which is why inhibitors of this target class reduce gastric acid production.
Lansoprazole is developed by Dr. Reddy's Laboratories Ltd, an Indian pharmaceutical company whose shares trade under the ticker RDY. Dr. Reddy's sponsored the clinical work recorded for this asset, including a Phase 1 bioequivalence study conducted in India.
Lansoprazole is in Phase 1 development. It is an investigational small molecule and is not described as approved. The single registered trial for this asset was a Phase 1 study, and it has completed, with no active trials currently listed.
Lansoprazole has been studied in trial NCT01270308, titled Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions. That Phase 1 trial enrolled 48 healthy adult volunteers in India, used an active-controlled, randomized design, and is now completed.
Yes. The registered Phase 1 trial of Lansoprazole, NCT01270308, was conducted in healthy volunteers rather than in patients with a specific disease. It enrolled 48 participants of any sex, aged 18 years and older, under fasting conditions in India.